Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;41(5):589-612.
doi: 10.1053/j.seminoncol.2014.07.003. Epub 2014 Jul 21.

GD2-targeted Immunotherapy and Radioimmunotherapy

Affiliations
Free PMC article
Review

GD2-targeted Immunotherapy and Radioimmunotherapy

Konstantin Dobrenkov et al. Semin Oncol. .
Free PMC article

Abstract

Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. They include pediatric embryonal tumors (neuroblastoma, retinoblastoma, brain tumors, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma), as well as adult cancers (small cell lung cancer, melanoma, soft tissue sarcomas). Because of its restricted normal tissue distribution, GD2 has been proven safe for antibody targeting. Anti-GD2 antibody is now incorporated into the standard of care for the treatment of high-risk metastatic neuroblastoma. Building on this experience, novel combinations of antibodies, cytokines, cells, and genetically engineered products all directed at GD2 are rapidly moving into the clinic. In this review, past and present immunotherapy trials directed at GD2 will be summarized, highlighting the lessons learned and the future directions.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

Publication types

Feedback